Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?

被引：1
|
作者：
Domenech, E. [1 ,2 ]
Canete, F. [1 ]
Manosa, M. [1 ,2 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, IBD Unit, Barcelona, Spain
[2] CIBEREHD, Barcelona, Spain
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2017年 / 46卷 / 11-12期
关键词：
INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; INFLIXIMAB; COMBINATION; ADALIMUMAB; INDUCTION; TRIAL;
D O I：
10.1111/apt.14350
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1113 / 1114
页数：2
相关论文
共 50 条
  • [41] ANTI-DRUG ANTIBODIES AS A PREDICTOR FOR THE DISCONTINUATION OF ANTI-TNF AGENTS IN PATIENTS WITH SPONDYLOARTHRTIS
    Kim, H. J.
    Hwang, J.
    Kim, I.
    Jeong, H.
    Lee, J.
    Jeon, C. H.
    Koh, E. -M.
    Cha, H. -S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 717 - 718
  • [42] Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease
    Papamichael, K.
    Cheifetz, A. S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (03) : 436 - 437
  • [43] Are We Ready for Proactive Therapeutic Drug Monitoring of Anti-TNF to Optimize Care of Patients With Inflammatory Bowel Disease?
    Charabaty, Aline
    CROHNS & COLITIS 360, 2020, 2 (01)
  • [44] Utility of therapeutic anti-TNF drug monitoring in hospitals with different degree of experience in the treatment of inflammatory bowel disease
    Vila, M.
    Bahi, A.
    Miquel, J. O.
    Busquets, D.
    Salo, J.
    Aldeguer, X.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S90 - S90
  • [45] Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
    Marquez-Megias, Silvia
    Nalda-Molina, Ricardo
    Sanz-Valero, Javier
    Mas-Serrano, Patricio
    Diaz-Gonzalez, Marcos
    Candela-Boix, Maria Remedios
    Ramon-Lopez, Amelia
    PHARMACEUTICS, 2022, 14 (05)
  • [46] Anti-Drug Antibodies As a Predictor for the Discontinuation of Anti-TNF Agents in Patients with Spondyloarthrtis.
    Hwang, Jiwon
    Kim, In Young
    Lee, Seulkee
    Jeong, Hyemin
    Kim, Hyungjin
    Lee, Jaejoon
    Koh, Eun-mi
    Cha, Hoon-Suk
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S263 - S263
  • [47] Relevance of anti-drug antibodies in context of supra-therapeutic anti-TNF concentrations
    Kim, J.
    Walshe, M.
    Borowski, K.
    Milgrom, R.
    Stempak, J.
    Lee, S. H.
    Croitoru, K.
    Silverberg, M. S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I933 - I934
  • [48] Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications
    Levy, Roger A.
    Guzman, Renato
    Castaneda-Hernandez, Gilberto
    Martinez-Vazquez, Manuel
    Damian, Guilherme
    Cara, Carlos
    IMMUNOTHERAPY, 2016, 8 (12) : 1427 - 1436
  • [49] Anti-TNF therapeutic agents in inflammatory bowel disease: indications, side effects and management
    Cocq, P
    Yazdanpannah, Y
    Mesnard, B
    Colombel, JF
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 : D61 - D69
  • [50] Lower Therapeutic Response to Anti-TNF Agents in African Americans with Inflammatory Bowel Disease
    Owings, Anna H.
    Burstiner, Landen
    Royer, Amor
    Johnson, Jeshanah
    Barr, Madelyn
    Hreish, Yousef
    Bradley, Lauren
    Edwards, Kane
    Brar, Himmat
    Laird, Hannah
    Claggett, Brian
    Liu, Julia
    Glover, Sarah C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S326 - S327
12345